See more : PAO TMK (TRMK.ME) Income Statement Analysis – Financial Results
Complete financial analysis of Novartis AG (NVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novartis AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- SmileDirectClub, Inc. (SDCCQ) Income Statement Analysis – Financial Results
- Amraworld Agrico Limited (AMRAAGRI.BO) Income Statement Analysis – Financial Results
- Ener-Core, Inc. (ENCR) Income Statement Analysis – Financial Results
- Pacific Horizon Investment Trust PLC (PHI.L) Income Statement Analysis – Financial Results
- European Metals Holdings Limited (EMHLF) Income Statement Analysis – Financial Results
Novartis AG (NVS)
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.66B | 51.83B | 52.88B | 49.90B | 48.68B | 53.17B | 50.14B | 49.44B | 50.39B | 53.63B | 58.83B | 57.56B | 59.38B | 51.56B | 45.10B | 42.58B | 38.95B | 36.75B | 32.53B | 28.25B | 24.86B | 23.15B | 19.34B | 21.83B | 20.42B | 23.04B |
| Cost of Revenue | 12.47B | 15.49B | 15.87B | 15.12B | 14.43B | 18.41B | 17.18B | 17.52B | 17.40B | 17.35B | 19.61B | 18.76B | 18.98B | 14.49B | 12.18B | 11.44B | 11.03B | 10.30B | 8.87B | 6.63B | 5.89B | 5.44B | 4.76B | 6.25B | 5.23B | 7.31B |
| Gross Profit | 34.19B | 36.34B | 37.01B | 34.78B | 34.25B | 34.76B | 32.96B | 31.92B | 32.98B | 36.29B | 39.22B | 38.81B | 40.39B | 37.07B | 32.92B | 31.15B | 27.92B | 26.45B | 23.66B | 21.62B | 18.97B | 17.71B | 14.58B | 15.59B | 15.19B | 15.73B |
| Gross Profit Ratio | 73.27% | 70.12% | 69.99% | 69.70% | 70.37% | 65.38% | 65.74% | 64.56% | 65.46% | 67.66% | 66.67% | 67.42% | 68.03% | 71.90% | 73.00% | 73.14% | 71.67% | 71.97% | 72.74% | 76.55% | 76.30% | 76.50% | 75.39% | 71.40% | 74.39% | 68.29% |
| Research & Development | 11.37B | 10.00B | 9.54B | 8.98B | 9.40B | 9.07B | 8.97B | 9.04B | 8.94B | 9.09B | 9.85B | 9.33B | 9.58B | 9.07B | 7.47B | 7.22B | 6.43B | 5.35B | 4.85B | 4.21B | 3.76B | 3.10B | 2.53B | 2.84B | 2.67B | 2.71B |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.47B | 2.14B | 2.19B | 2.48B | 2.62B | 3.06B | 2.94B | 2.97B | 2.48B | 2.28B | 2.25B | 2.13B | 1.96B | 1.74B | 1.54B | 0.00 | 8.98B | 7.66B | 7.94B | 6.95B | 1.29B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.86B | 12.00B | 11.77B | 12.38B | 14.55B | 14.35B | 15.08B | 13.32B | 12.05B | 11.85B | 11.13B | 10.45B | 9.80B | 8.87B | 9.33B | 0.00 | 0.00 | 0.00 | 0.00 | 6.39B |
| SG&A | 12.49B | 14.25B | 14.89B | 14.20B | 14.37B | 16.47B | 15.00B | 14.19B | 14.25B | 14.99B | 17.61B | 17.29B | 18.05B | 15.80B | 14.33B | 14.10B | 13.26B | 12.41B | 11.54B | 10.41B | 9.33B | 8.98B | 7.66B | 7.94B | 6.95B | 7.68B |
| Other Expenses | 559.00M | 2.90B | 895.00M | 1.45B | 1.40B | 1.05B | 362.00M | 417.00M | 824.00M | 1.12B | 852.00M | 672.00M | 1.76B | 680.00M | 1.14B | 867.00M | 1.45B | 741.00M | 363.00M | 463.00M | 0.00 | 0.00 | 0.00 | 0.00 | 949.00M | 0.00 |
| Operating Expenses | 24.42B | 27.15B | 25.32B | 24.63B | 25.17B | 26.59B | 24.33B | 23.65B | 24.01B | 25.20B | 28.31B | 27.29B | 29.39B | 25.55B | 22.94B | 22.18B | 21.13B | 18.50B | 16.75B | 15.08B | 13.08B | 12.08B | 10.18B | 10.78B | 10.57B | 10.39B |
| Cost & Expenses | 36.89B | 42.63B | 41.19B | 39.75B | 39.59B | 45.00B | 41.51B | 41.17B | 41.41B | 42.55B | 47.92B | 46.05B | 48.38B | 40.04B | 35.12B | 33.62B | 32.17B | 28.80B | 25.62B | 21.71B | 18.98B | 17.52B | 14.94B | 17.03B | 15.80B | 17.69B |
| Interest Income | 627.00M | 379.00M | 71.00M | 91.00M | 245.00M | 294.00M | 110.00M | 43.00M | 33.00M | 33.00M | 34.00M | 50.00M | 62.00M | 103.00M | 156.00M | 306.00M | 423.00M | 367.00M | 405.00M | 388.00M | 323.00M | 416.00M | 293.00M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 855.00M | 837.00M | 811.00M | 869.00M | 850.00M | 957.00M | 777.00M | 707.00M | 655.00M | 704.00M | 683.00M | 724.00M | 751.00M | 692.00M | 551.00M | 290.00M | 237.00M | 266.00M | 294.00M | 261.00M | 243.00M | 259.00M | 218.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28B | 6.71B | 5.43B | 5.11B | 5.83B | 5.21B | 5.21B | 5.35B | 5.58B | 4.75B | 4.99B | 4.95B | 5.79B | 3.42B | 2.30B | 2.67B | 2.86B | 1.99B | 1.72B | 1.34B | 1.28B | 690.00M | 585.00M | 918.00M | 949.00M | 1.01B |
| EBITDA | 18.29B | 14.73B | 17.13B | 15.24B | 15.01B | 14.14B | 13.90B | 13.19B | 14.36B | 17.66B | 15.90B | 16.92B | 17.09B | 15.81B | 12.77B | 12.46B | 10.58B | 10.18B | 8.78B | 7.97B | 7.26B | 5.90B | 4.41B | 5.63B | 5.56B | 6.35B |
| EBITDA Ratio | 39.19% | 31.62% | 62.52% | 34.49% | 32.08% | 40.91% | 31.71% | 30.42% | 28.51% | 33.05% | 27.89% | 29.40% | 29.20% | 30.67% | 28.18% | 28.96% | 26.75% | 28.62% | 28.21% | 29.63% | 29.21% | 25.50% | 22.82% | 24.68% | 25.46% | 27.58% |
| Operating Income | 9.77B | 9.20B | 26.95B | 10.15B | 9.09B | 8.17B | 8.63B | 8.27B | 8.98B | 11.09B | 10.91B | 11.51B | 11.00B | 11.53B | 9.98B | 8.96B | 6.78B | 7.95B | 6.91B | 6.54B | 5.89B | 5.63B | 4.39B | 4.81B | 4.62B | 5.35B |
| Operating Income Ratio | 20.94% | 17.75% | 50.96% | 20.35% | 18.67% | 15.37% | 17.21% | 16.72% | 17.82% | 20.68% | 18.54% | 20.00% | 18.52% | 22.35% | 22.13% | 21.05% | 17.41% | 21.63% | 21.23% | 23.15% | 23.68% | 24.34% | 22.72% | 22.01% | 22.62% | 23.20% |
| Total Other Income/Expenses | -646.00M | 425.00M | -16.15B | -274.00M | -146.00M | -746.00M | -811.00M | -451.00M | -843.00M | 1.18B | -176.00M | -271.00M | -225.00M | 176.00M | -60.00M | 94.00M | 294.00M | -219.00M | 360.00M | -129.00M | -155.00M | 64.00M | 367.00M | 789.00M | 714.00M | 408.43M |
| Income Before Tax | 9.12B | 8.37B | 26.14B | 9.88B | 8.94B | 13.84B | 9.00B | 7.82B | 8.13B | 12.27B | 10.74B | 11.24B | 10.77B | 11.70B | 9.92B | 9.50B | 7.49B | 8.30B | 7.27B | 6.91B | 6.07B | 6.29B | 5.11B | 5.51B | 5.34B | 5.79B |
| Income Before Tax Ratio | 19.55% | 16.15% | 49.43% | 19.80% | 18.37% | 26.02% | 17.95% | 15.81% | 16.14% | 22.88% | 18.25% | 19.53% | 18.14% | 22.70% | 22.00% | 22.31% | 19.22% | 22.59% | 22.34% | 24.46% | 24.40% | 27.17% | 26.42% | 25.22% | 26.16% | 25.14% |
| Income Tax Expense | 551.00M | 1.42B | 2.12B | 1.81B | 1.79B | 1.22B | 1.30B | 1.12B | 1.11B | 1.55B | 1.44B | 1.63B | 1.53B | 1.73B | 1.47B | 1.34B | 947.00M | 1.28B | 1.12B | 1.13B | 1.01B | 1.07B | 869.00M | 1.11B | 1.15B | 1.37B |
| Net Income | 14.85B | 6.96B | 24.02B | 8.07B | 7.15B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B | 9.18B | 9.51B | 9.11B | 9.79B | 8.40B | 8.20B | 11.95B | 7.18B | 6.13B | 5.77B | 5.02B | 5.22B | 4.24B | 4.40B | 4.19B | 4.41B |
| Net Income Ratio | 31.83% | 13.42% | 45.43% | 16.18% | 14.68% | 23.72% | 15.36% | 13.58% | 35.29% | 19.04% | 15.60% | 16.51% | 15.35% | 18.99% | 18.62% | 19.24% | 30.67% | 19.52% | 18.85% | 20.42% | 20.17% | 22.56% | 21.92% | 20.13% | 20.51% | 19.13% |
| EPS | 7.15 | 3.19 | 10.71 | 3.54 | 3.12 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 | 3.76 | 3.93 | 3.75 | 4.28 | 3.70 | 3.62 | 5.15 | 3.06 | 2.63 | 2.28 | 1.99 | 1.88 | 1.49 | 1.70 | 0.62 | 0.33 |
| EPS Diluted | 7.10 | 3.17 | 10.63 | 3.52 | 3.08 | 5.38 | 3.25 | 2.80 | 7.29 | 4.13 | 3.70 | 3.89 | 3.70 | 4.26 | 3.69 | 3.59 | 5.13 | 3.04 | 2.62 | 2.27 | 1.97 | 1.84 | 1.49 | 1.70 | 0.62 | 0.33 |
| Weighted Avg Shares Out | 2.08B | 2.18B | 2.24B | 2.28B | 2.29B | 2.32B | 2.35B | 2.38B | 2.40B | 2.43B | 2.44B | 2.42B | 2.38B | 2.29B | 2.27B | 2.27B | 2.32B | 2.35B | 2.33B | 2.36B | 2.38B | 2.52B | 2.57B | 2.63B | 2.62B | 2.74B |
| Weighted Avg Shares Out (Dil) | 2.09B | 2.20B | 2.26B | 2.30B | 2.32B | 2.34B | 2.37B | 2.40B | 2.44B | 2.47B | 2.48B | 2.44B | 2.41B | 2.30B | 2.28B | 2.28B | 2.33B | 2.36B | 2.34B | 2.37B | 2.41B | 2.57B | 2.58B | 2.63B | 2.62B | 2.74B |
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.
Novartis AG (NVS) Renal Portfolio Update Call Transcript
Novartis AG (NYSE:NVS ) Renal Portfolio Update Conference Call October 28, 2024 8:00 AM ET Company Participants Sloan Simpson - Head, Investor Relations Shreeram Aradhye - President, Global Drug Development and CMO Victor Bulto - President, U.S. Business Dave Soergel...
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs
Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S.-based biotech firm said on Monday.
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 glomerulopathy (C3G) treated with oral Fabhalta® (iptacopan) in addition to...
NVS vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
What To Expect When Novartis Reports Q3 2024 Results
Novartis will report Q3 results next week and I expect the company to beat EPS and revenue estimates, and increase the full-year revenue and core operating income guidance. Key growth products should drive high single-digit revenue growth in the third...
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
3 Absurdly Cheap Stocks That Pay High Dividends
These stocks are trading at less than 15 times their expected future profits.
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Basel, October 24, 2024 – This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for breast cancer were updated to recommend ribociclib (Kisqali®) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients with hormone receptor-positive/human...
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Source: https://incomestatements.info
Category: Stock Reports